EU Accelerated Assessment Tracker: Rejection Is Standard Outcome For Fast-Track Requests This Year

Attempts by companies to have their investigational products fast-tracked through the EU approval system this year so far have largely failed. Often the same products have or had priority review in the US. With the European Medicines Agency deciding on four new accelerated assessment requests this week, will the tide start to turn?

Row of pencil tops enter on an angle from bottom right with erasers flush and pointing toward center. Seventh pencil in stands out with sharpened lead tip jutting out further than adjacent erasers.
Fast-Track Status Can Give Companies The Edge Over Competitors

Just one of the seven requests for accelerated assessment that the European Medicines Agency has processed this year is known to have been successful. One request has been granted, four have been denied and the outcomes of two are unknown.

Decisions are due to be taken on a further four requests this week. Also see " New EU Speedy...

More from Review Pathways

PS-Pathways&Standards (Free-1): Industrial Chemicals Within Us - The Ubiquity of Industrial Products in the Human Body

 
• By 

Exploring How Everyday Industrial Compounds Enter Our Systems, Their Health Implications, and the Ongoing Quest for Safer Alternatives .

Brazil Issues Guidance On Regulatory Reliance & Equivalent Authorities

 

Brazilian regulator Anvisa is relying on the decisions of its foreign counterparts as a means of ensuring more quality medicines are made available in the country.

Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva

 
• By 

The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.

UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures

 
• By 

The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.

More from Pathways & Standards

Anvisa To Access US FDA-Reviewed Data For More Robust Evaluations In Brazil

 

Brazil has also published its recent regulatory reliance regulations in English, a move designed to increase confidence in its decisions as it presses on with aligning its national practices with global best practices.

Califf: Rare Disease Hub Will Develop Methods To Guide Approvability Determinations

 

The US FDA commissioner also said the hub is looking for an executive director who will work with the CBER and CDER heads, who will serve as co-leads.

Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva

 
• By 

The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.